Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087370 | 0.96 | HRH3 (0.48) | HRH3S1PR2ESR2MAPK1NR1H2 | |
| SCHEMBL3089890 | 0.90 | STS (0.47) | ESR2MAPK1NR1H2STSPDE4B | |
| SCHEMBL3087527 | 0.89 | HRH3 (0.48) | HRH3S1PR2ESR2NR1H2STS | |
| SCHEMBL3089541 | 0.89 | ESR2 (0.47) | ESR2MAPK1NR1H2STSPDE4B | |
| SCHEMBL3082431 | 0.89 | ESR2 (0.49) | HRH3S1PR2ESR2NR1H2STS | |
| SCHEMBL3094927 | 0.86 | STS (0.47) | ESR2MAPK1NR1H2STSPDE4B | |
| SCHEMBL3091109 | 0.86 | NR1H2 (0.46) | HRH3S1PR2ESR2NR1H2HDAC6 | |
| SCHEMBL3090139 | 0.85 | TTR (0.49) | ESR2MAPK1NR1H2STSPDE4B | |
| SCHEMBL3077276 | 0.81 | HRH3 (0.66) | HRH3S1PR2ESR2NR1H2 | |
| SCHEMBL3085962 | 0.80 | ESR2 (0.46) | HRH3S1PR2ESR2NR1H2STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2133340-B1 | Novel benzazepine derivatives | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| US-8207331-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-7799773-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7704994-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-7696193-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| EP-2133340-A1 | Novel benzazepine derivatives | Glaxo Group Limited (GB) | 2009-12-16 | — | — | EP | disclosed |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK JAMES | 2009-04-23 | — | — | US | disclosed |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK J | 2007-12-27 | — | — | US | disclosed |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1572215-A1 | BENZO[D]AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056369-A1 | BENZO ‘ D!AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | DRD1, DRD2, DRD3 | HRH3 211/4885S1PR2 1975/4885ESR2 1181/4885 |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, GRIN2A, GRIN2B | HRH3 450/4885S1PR2 1388/4885ESR2 2190/4885 |
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GRIN2C, GRIN2A, GRIN2B | HRH3 450/4885S1PR2 1388/4885ESR2 2190/4885 |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, TPH1, GRIN2B | HRH3 243/4885S1PR2 996/4885ESR2 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.